Not Cited

Front 1

Ding (2011)

Back 1

I find that firms with proportionally more Ph.D. - holding entrepreneurs on the founding team have a higher probability of adopting open science. In addition, founders’ educational background can mitigate the constraint of organizational environments on strategy. A crowded technological niche provides a more challenging environment for firms for implementing open science, due to higher scooping risks. The deterring effect, however, of such a high-risk environment is smaller among firms founded by proportionally more Ph.D. - holding entrepreneurs.

Front 2

Khourya and Pleggenkuhle-Miles (2011)

Back 2

Using a sample of 11,593 patents produced by 256 biotechnology firms from 1985 to 2006, we find that prior joint invention experience diversifies the capabilities of the firm and broadens its strategic options. In uncovering an inverted ‘U’ relationship, we also find that capabilities evolve differently according to the firm's unique joint invention experiences. Moreover, firms that continue to engage in more joint invention experiences develop broader capabilities than firms that retreat from this strategy and pursue solo inventions, whereby more specialized capabilities develop

Front 3

Yanfeng , Liub, , George (2009)

Back 3

The dynamic impact of innovative capability and inter-firm network on firm valuation: A longitudinal study of biotechnology start-ups

Our results confirm the positive effect of innovative capability on firm performance in technology start-ups, consistent with other studies (

Front 4

1.Al-Laham1, . Amburgey, Charles Baden-Fuller (2010)

Back 4

we hypothesize that cooperative arrangements that only gain access to external knowledge contribute less to heterogeneity between firms and have a much weaker influence on patenting than alliances that transfer highly firm-specific knowledge, residing in individual and social relationships. We also hypothesize that cooperations between private firms and public organizations accelerate the rate of patenting to a higher degree than cooperations among private firms

Front 5

Zahra (1996)

Back 5

Indeoendent ventures and corporate ventures in biotech start-ups

Front 6

Qian, Lee Li (2003)

Back 6

This paper investigates the profitability determinants of small- and medium-sized enterprises in high-tech industries. Literature review suggests that innovator position, market awareness, niche operation, and internationalization should have positive impacts on SMTEs' profitability.

Front 7

Hess and Rothaermel (2011) August

Back 7

When are assets complementary? star scientists, strategic alliances, and innovation in the pharmaceutical industry

Front 8

Wu (2010)

Back 8

This study uses a group of informants and applies a step-by-step empirical process to examine the applicability of the resource-based view (RBV) and dynamic-capability view (DCV) to environmental volatility. Through examining 253 Taiwanese firms, this study finds that the explanatory power of DCV exceeds that of RBV in volatile environments.

Front 9

Patzel et al 2008

Back 9

. Our results also show that managers' experience collected in the pharmaceutical industry has a positive effect on performance, and that this effect is more positive for therapeutics than for platform ventures

Front 10

Lozinick and Tulum (2011) July

Back 10

In the decade before the 2008 economic crisis, the US biotechnology industry was booming. In a 2006 book, Science Business: The Promise, the Reality, and the Future of Biotech, Gary Pisano implies that, given the 10–20 year time-frame for developing biotech products and the lack of profitability of the industry as a whole, the US biotech boom should not have happened. Yet the biotech industry has received substantial funding from venture-capital firms as well as from established companies through R&D alliances. Why would money from venture capitalists and big pharma flow into an industry in which profits are so hard to come by?

Front 11

Bae, Wezel , Koo 2011

Back 11

This study examines the role of cooperative relations among incumbents in the formation of new firms. We argue that cooperative interfirm relations that bridge geographically remote and diverse sources of knowledge—cross-cutting ties—contribute to new firm formation. Employing data on state-level entries into the U.S. biotech industry from 1994 to 1998, we find support for the following hypotheses: the formation of new firms in a focal region of an industry is positively related to the number of cross-cutting ties; the number of cross-cutting ties negatively moderates the effects of organizational density on the formation of new firms.

Front 12

Catherine 1, Corolleur 2, Carrère 3, Mangematin (2004)

Back 12

This paper examines how scientific and technological (S&T) human capital is transformed into financial capital through the creation of firms by scientists. The analysis is based on a database describing the positions held by 132 founders from 62 French biotech SMEs. It shows that star scientists engage in highly risky but also valuable firms. Less famous scientists must develop their human capital rather than valorising a stock. The paper concludes by pointing to three paradoxes concerning the commitment and compensation scheme of star scientists and the managerial position of less known scientists.